DOI:
10.1055/s-00000036
Laryngo-Rhino-Otologie
LinksClose Window
References
Takahashi H, Tada Y, Saotome T. et al.
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
J Clin Oncol 2019;
37 (02) 125-134
DOI: 10.1200/JCO.18.00545. (PMID: 30452336)
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.